Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Defiance Pure Space Daily 2X Strategy ETF
IES Holdings, Inc. - Common Stock
National Bank of Canada
Sanwire Corp
Verde Clean Fuels, Inc. - Class A Common Stock
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
37.53
-0.22 (-0.58%)
Delayed Quote
Updated: 3:28 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Xenon (XENE) Q3 2026 Earnings Call Transcript
↗
November 10, 2026
Xenon's NDA filing and pain drug data point to a busy stretch ahead.
Via
The Motley Fool
Topics
Earnings
Xenon Pharmaceuticals Q3 Earnings Call Highlights
↗
November 09, 2026
Xenon Pharmaceuticals (NASDAQ:XENE) expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and...
Via
MarketBeat
Topics
Earnings
Xenon Reports Q3 2026 Financial Results and Provides Business Update
November 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at Upcoming Investor Conferences
November 03, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup
↗
August 13, 2026
Via
Chartmill
Xenon to Report Q3 2026 Financial Results on November 9, 2026
November 02, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
October 29, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
↗
September 27, 2026
Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program...
Via
MarketBeat
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
September 23, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 21, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Triple Witching Whipsaws Wall Street While Crypto Stocks Steal the Show
↗
September 21, 2026
Via
Chartmill
Top stock movements in today's session.
↗
September 18, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
September 18, 2026
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
September 18, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
September 18, 2026
Via
Chartmill
These stocks are moving in today's after hours session
↗
September 17, 2026
Via
Chartmill
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
September 17, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at Wells Fargo Healthcare Conference
September 03, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
August 26, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Azetukalner advances toward FDA submission as pain pipeline matures.
Via
The Motley Fool
Topics
Earnings
Xenon Pharmaceuticals Q2 Earnings Call Highlights
↗
August 07, 2026
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in...
Via
MarketBeat
Topics
Earnings
Xenon Reports Q2 2026 Financial Results and Provides Business Update
August 06, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q2 2026 Financial Results on August 6, 2026
July 30, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
↗
May 18, 2026
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1